Efficacy News and Research

RSS

EMA CHMP issues positive opinion to MSD's REMICADE for treatment of pediatric UC

MSD today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending the use of REMICADE (infliximab) in the treatment of severely active ulcerative colitis (UC) in pediatric patients ages 6 to 17 years, who have had an inadequate response to conventional therapy, including corticosteroids and 6-mercaptopurine or azathioprine, or who are intolerant to or have medical contraindications for such therapies.

21 Jan 2012

Risperdal lawsuit settlement: Largest Medicaid fraud case in Texas

Texas and Janssen Pharmaceuticals reach a $158 million settlement on a suit claiming that the company lied about the efficacy of the anti-psychotic medicine.

21 Jan 2012

Awake ECMO may be an effective bridging strategy for lung transplantation candidates

Extracorporeal membrane oxygenation (ECMO) support in awake, non-intubated patients may be an effective strategy for bridging patients to lung transplantation, according to a new study from Germany.

21 Jan 2012

Combination of gefitinib and miRNA-inhibitor might effectively treat NSCLC

New research published in Nature Medicine indicates that targeted drugs such as gefitinib might more effectively treat non-small cell lung cancer if they could be combined with agents that block certain microRNAs.

20 Jan 2012

Banner Alzheimer's Institute presents results from Navidea AZD4694 study at 6th Annual HAI

Navidea Biopharmaceuticals, Inc. today announced that the Banner Alzheimer's Institute, Phoenix, AZ, made two presentations of results from an AstraZeneca-sponsored study on the assessment of Navidea's late-stage radiopharmaceutical imaging candidate, AZD4694, at the 6th Annual Human Amyloid Imaging Meeting (HAI), in Miami, FL.

20 Jan 2012

FDA issues complete response letter to Bristol-Myers Squibb and AstraZeneca's dapagliflozin

Bristol-Myers Squibb Company and AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter regarding the New Drug Application (NDA) for investigational compound dapagliflozin for the treatment of type 2 diabetes in adults.

19 Jan 2012

Experimental drug helps patients with advanced colon cancer

According to results from a new clinical trial, an experimental cancer drug regorafenib appears to extend survival slightly in patients with metastatic colorectal cancer. Regorafenib is a so-called multikinase inhibitor, which targets several of the ways cancer develops and grows, researchers said.

19 Jan 2012

Proceedings from Workshop on Effective Use of Fluoride in Asia

The International and American Associations for Dental Research (IADR/AADR) have published the proceedings from the Workshop on Effective Use of Fluoride in Asia, which took place March 22-24, 2011, in Phan-Nga, Thailand.

19 Jan 2012

Interprofessional seminar on teamwork in medicine

Advances in medical technology, changes in health care delivery and an aging, ailing population have all made the practice of medicine increasingly dependent on clinical collaboration. Yet most health care students rarely gain understanding or even exposure to the many other types of specialists, professionals, administrators, or statisticians they will deal with in the real world.

19 Jan 2012

Biotectix announces FIH use of electrostimulation device with BT DOT polymer coatings

Biotectix, LLC, an Allied Minds, Inc. subsidiary, is pleased to announce the first-in-human (FIH) use of an electrostimulation device incorporating its BT DOT conductive polymer coating technology.

19 Jan 2012

Gilead Sciences receives FDA approval for Viread to treat pediatric HIV infection

Gilead Sciences, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved Viread in combination with other antiretroviral agents for the treatment of HIV-1 infection in pediatric patients ages 2-12.

19 Jan 2012

Live interactive consultations can improve clinical outcomes for patients

UC Davis Health System dermatologists, using videoconferencing technology known as teledemedicine, have determined that live interactive consultations can improve clinical outcomes for patients because they usually involve beneficial changes in medical diagnosis and disease management that otherwise might not occur.

19 Jan 2012

Cangrelor allows stent patients to be 'bridged' to cardiac surgery

New findings from a research study led by physicians at Scripps Health reveal that the investigational drug cangrelor has the unique properties of achieving very fast blood thinning effects when needed to protect from heart attacks, but also dissipates rapidly so patients can undergo surgery without the excessive bleeding often associated with blood thinning medications.

18 Jan 2012

Minimally invasive renal denervation performed for the first time in Canada

Doctors at the Peter Munk Cardiac Centre today performed a minimally invasive surgical procedure to treat high blood pressure, called renal denervation, for the first time in Canada.

18 Jan 2012

Memory retraining using mSMT increases cerebral activation in MS patients

Neuroscientists at Kessler Foundation have documented increased cerebral activation in patients with multiple sclerosis (MS) following memory retraining using the modified Story Memory Technique (mSMT).

18 Jan 2012

Peter Munk Cardiac Centre doctors perform renal denervation in first Canadian patient

Doctors at the Peter Munk Cardiac Centre today performed a minimally invasive surgical procedure to treat high blood pressure, called renal denervation, for the first time in Canada. The procedure can significantly reduce high blood pressure in patients who cannot effectively treat their hypertension through drugs. These patients, numbering approximately 250,000 Canadians, have to endure an especially high risk of heart attacks and stroke, which continues to kill thousands of Canadians every year.

18 Jan 2012

Paragon receives JVAP-CBMS contract from DoD

Paragon Bioservices, Inc., a Baltimore-based CMO focused on the process development and manufacturing of biologics, announced today that it has been awarded a JVAP-CBMS contract from the Department of Defense (DoD) for the vaccine development and subsequent GMP manufacturing of the "VEE Replicon Particle Trivalent Filovirus Vaccine."

18 Jan 2012

New combination treatment more effective in treating cutaneous T-Cell lymphoma

Promising findings on a novel combination treatment approach for a chronic type of skin lymphoma are being published in JAMA's Archives of Dermatology by clinical researchers from Seidman Cancer Center at University Hospitals (UH) Case Medical Center and Case Western Reserve University School of Medicine.

18 Jan 2012

Ivera receives new FDA clearance for Curos disinfecting port protector

Ivera Medical Corporation today announced it has received a new FDA 510(k) clearance for its Curos disinfecting port protector which reflects the company's ongoing determination to continuously improve its products to better deliver solutions designed to reduce hospital-acquired catheter related bloodstream infections.

18 Jan 2012

LEITAT, JPT and IUCT partner to develop enhanced anticancer therapy

JPT Peptide Technologies GmbH (JPT), a wholly-owned subsidiary of BioNTech AG, IUCT and LEITAT announced today their collaboration on the joint development of an enhanced anticancer therapy based on the biofocused targeting of nucleoside analogs linked to small cyclic peptidomimetics.

18 Jan 2012